Protein / target

Myosin-6

MYH6P13533Homo sapiensSwiss-Prot
UniProt: P13533Ensembl: ENSG00000197616HGNC: HGNC:7576NCBI Gene: 4624
Clinically validated
Therapeutic maturity
2
Approved medicines
10
Clinical trials
Small-molecule tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Microfilament motor activity

Primary system

Cardiovascular system

Strongest disease association

dilated cardiomyopathy 1EE

Genetic evidence · score 0.85

Therapeutic maturity

Clinically validated target

2 approved medicines against this target

Druggability

Small molecule

Open Targets tractability · Approved Drug

Clinical development

2 approved · 1 in clinical development

10 linked trials

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function

Muscle contraction

Subcellular location

Cytoplasm, myofibril
Domains and Gene Ontology detail (36)

Domains & features

Myosin N-terminal SH3-likeMyosin motorIQ

Gene Ontology

  • Ccytoplasm
  • Ccytosol
  • Cmuscle myosin complex
  • Cmyofibril
  • Cmyosin complex
  • Cmyosin filament
  • Cmyosin II complex
  • Csarcomere
  • Cstress fiber
  • CZ disc
  • Factin filament binding
  • FATP binding

1939 aa · 224 kDa

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Muscle contractionUniProt · GO · ReactomeKinase signallingGOMetabolic enzyme activityGO
View supporting evidence

Muscle contraction

  • ·Muscle contraction
  • ·muscle myosin complex
  • ·myosin complex
  • ·myosin filament

Kinase signalling

  • ·protein kinase binding

Metabolic enzyme activity

  • ·ATP metabolic process
View underlying pathways (1)
Striated Muscle Contraction

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

MYH7MYL3MYL2MYBPC3ACTC1ACTN2MYL4TNNI1TNNT2MYL1MYH6

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Drugs targeting this protein

1

Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.

omecamtiv mecarbil
ApprovedActivator

Cardiac myosin activator

Appears in clinical studies involving cardiovascular disorder, heart failure, heart failure, Stroke

Acts on a complex — shared with MYH7, MYH7B, MYL3 +3 more · 1 of 7 recorded protein targets

ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.

Translational evidence

Open Targets 26

Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.

Strongest genetic associations

Human genetic evidence — the most direct causal link between this target and a disease.

dilated cardiomyopathy 1EE0.85

Genetic · overall 0.74

hypertrophic cardiomyopathy 140.85

Genetic literature · overall 0.65

atrial septal defect 30.76

Genetic literature · overall 0.72

atrial fibrillation0.71

Genetic · overall 0.45

Rare familial disorder with hypertrophic cardiomyopathy0.69

Genetic · overall 0.45

Highest-confidence therapeutic associations

Diseases where a drug acting on this target has already reached clinical development.

hypertrophic cardiomyopathy0.95

Clinical · overall 0.75

cardiovascular disorder0.76

Clinical · overall 0.46

Highest overall evidence

Remaining associations by Open Targets' aggregated evidence score.

familial isolated dilated cardiomyopathy0.59

Animal model

atrial septal defect0.54

Genetic literature

hypertrophic cardiomyopathy 10.44

Animal model

Show all associations
hypertrophic cardiomyopathy0.75
dilated cardiomyopathy 1EE0.74
atrial septal defect 30.72
hypertrophic cardiomyopathy 140.65
familial isolated dilated cardiomyopathy0.59
atrial septal defect0.54
cardiovascular disorder0.46
atrial fibrillation0.45
Rare familial disorder with hypertrophic cardiomyopathy0.45
hypertrophic cardiomyopathy 10.44

Open Targets ranks 734 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.

Known drugs · 3 total

DANICAMTIVPhase 2 3

dilated cardiomyopathy · heart failure · heart failure

OMECAMTIV MECARBILApproval

cardiovascular disorder · heart failure · heart failure

MAVACAMTENApproval

hypertrophic cardiomyopathy · cardiovascular disorder · hypertrophic cardiomyopathy

Tractability

SM · Approved DrugPR · Database Ubiquitination

Clinical trials

10

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.

Omecamtiv Mecarbil Post-trial Access Protocol for Subjects Completing Study 20110203 GALACTIC-HFPHASE3

WITHDRAWN · via omecamtiv mecarbil · NCT04464525

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart FailurePHASE2

COMPLETED · via omecamtiv mecarbil · NCT01300013

Single-dose and Randomized, Single-center, Placebo- and Active-controlled, Crossover Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy SubjectsPHASE1

COMPLETED · via omecamtiv mecarbil · NCT04175808

A Phase 1, Single Center Double-blind, Randomized, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Omecamtiv Mecarbil in Healthy Japanese SubjectsPHASE1

COMPLETED · via omecamtiv mecarbil · NCT02601001

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Assess Efficacy and Safety of Omecamtiv Mecarbil in Patients With Symptomatic Heart Failure With Severely Reduced Ejection Fraction (COMET-HF)PHASE3

RECRUITING · via omecamtiv mecarbil · NCT06736574

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure With Reduced Ejection Fraction and Decreased Exercise TolerancePHASE3

COMPLETED · via omecamtiv mecarbil · NCT03759392

Show remaining trials (4)
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection FractionPHASE2

COMPLETED · via omecamtiv mecarbil · NCT02695420

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF)PHASE3

COMPLETED · via omecamtiv mecarbil · NCT02929329

An Open Label, Multiple Dose Study to Investigate the Pharmacokinetics of Omecamtiv Mecarbil Administered Orally to Patients With Stable Heart FailurePHASE2

WITHDRAWN · via omecamtiv mecarbil · NCT01077167

A First-in-Man, Phase I, Double-Blind, Randomized, Four-Way Crossover, Placebo-Controlled, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of CK-1827452 (Omecamtiv Mecarbil) in Healthy VolunteersPHASE1

COMPLETED · via omecamtiv mecarbil · NCT01380223

ClinicalTrials.gov via the drug-target graph.

Forefront confidence

Synthesis

Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.

hypertrophic cardiomyopathyWell supported
0.94
agreement 0.84–1.00
Clinical40%Genetic38%Animal model20%Literature1%Genetic literaturedup

Open Targets aggregate 0.75 · 4 independent evidence families · 1 not counted as duplicate

dilated cardiomyopathy 1EEWell supported
0.90
agreement 0.77–1.00
Genetic74%Animal model26%Genetic literaturedup

Open Targets aggregate 0.74 · 2 independent evidence families · 1 not counted as duplicate

hypertrophic cardiomyopathy 14Well supported
0.88
agreement 0.76–1.00
Genetic74%Animal model26%Genetic literaturedup

Open Targets aggregate 0.65 · 2 independent evidence families · 1 not counted as duplicate

Rare familial disorder with hypertrophic cardiomyopathyWell supported
0.80
agreement 0.68–0.93
Genetic66%Animal model34%

Open Targets aggregate 0.45 · 2 independent evidence families

atrial fibrillationWell supported
0.80
agreement 0.68–0.92
Genetic69%Animal model26%Literature5%

Open Targets aggregate 0.45 · 3 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.

What's happening now

1

Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.

  1. New publication2020-11-13
    Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.

    The New England journal of medicine · 2021 · 443 citations · Europe PMC · via omecamtiv mecarbil

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.